Aptamers are chemically synthesized peptides or oligonucleotide molecules that bind to a specific target nucleic acid, protein, or lipid. Aptamers are used in various fields such as drug delivery, diagnostics, and therapeutics.

As per the latest research citing of the European Respiratory Journal 2016 report, the global prevalence rate of cough was 9.6%. The largest prevalence was in the Oceania region with 18.1% followed by Europe, America, Asia and Africa with 12.7%, 11.0%, 4.4% and 2.3% respectively.

The antimicrobial susceptibility test market had market size of 2,755.9 Mn in 2017 and will grow at a CAGR 4.7% and is anticipated to reach 4,159.2 Mn in 2026. World Health Organization (WHO) has stipulated stringent guidelines to life science industry and agriculturists to judiciously use antibiotics.

The global antihistamines market will grow at a CAGR of 8.7% during the forecast period from 2018 to 2026. Antihistamines exemplify a class of drugs that block the histamine type-1 (H1) receptors. H1-receptors are extensively scattered and predominantly found on smooth muscle of the gastrointestinal tract, bronchi, uterus, and large blood vessels.

The global anticoagulants market was valued at US$ 33,150.7 Mn in 2017 and expected to grow at compound annual growth rate (CAGR) of 6.6% during the forecast period from 2018 to 2026. Anticoagulants are prescribed to patients who are at higher risk of clot formation in the blood and reduce the risk of serious conditions such as strokes and heart attacks. Anticoagulants are also given to treat pulmonary embolism, deep vein thrombosis (DVT), atrial fibrillation and other cardiovascular diseases.

The global anticoagulant reversal drugs market expected to grow at compound annual growth rate (CAGR) of 15.3% during the forecast period from 2018 to 2026. Reversing the effects of anticoagulants including novel oral anticoagulants (NOACs), Vitamin K antagonist and others is a major concern in clinical practice especially during life-threatening bleeding episodes and emergency surgery. Approvals of NOACs in last decade has increased the usage of these factor Xa inhibitors in preventing and treating various medical conditions such as stroke, pulmonary embolism, atrial fibrillation, and deep vein thrombosis (DVT).

Anti-inflammatory therapeutics market expected to reach by US$ 130.6 Bn by 2026 with CAGR of 8.5% during the forecast period from 2018 to 2026. Biologics and immune selective anti-inflammatory derivatives (ImSAIDs) are the promising drugs classes playing major role in the market.

The growing prevalence of infections such as influenzas, ebola virus and HIV have brought significant changes in the outlook of the general population about infections and their management, and consequently in the consumption of anti-infective agents.

The anti-aging services market is set to reach from US$ 22,518.8 Mn in 2017 to US$ 35,597.9 Mn by 2026 at a compound annual growth rate (CAGR) of 5.3% during the forecast period from 2018 to 2026. Aging is a biological process of becoming older which is characterized by changes in physical appearances such as greying of hair, wrinkles on face, saggy skin and decreased skin tone and texture. Oxidative stress and unhealthy eating habits stimulates the formation of free radical species which promotes cellular aging. Rising external appearance consciousness and availability of diverse range anti-aging products drive the anti-aging services market growth.

Anemia treatment drugs market accounted for a market value of US$ 23,155.8 Mn in 2017 and projected to grow at a CAGR of 16.4% during the forecast period from 2018 to 2026. An abnormal decrease in the level of red blood cells, irregular red blood cell morphology, or inadequate concentration of haemoglobin in the blood results in anemia. Anemia is caused also due to numerous nutritional and non-nutritional factors such as infectious disease including malaria, soil-transmitted- helminthiasis, hookworm, and tuberculosis).

Allergy immunotherapy market accounted for a market value of US$ 1,499.0 Mn in 2017 and projected to grow at a CAGR of 10.1% during the forecast period from 2018 to 2026. Allergy immunotherapy helps to prevent or minimize the allergic reactions and provide log-term benefit to patients. This therapy helps to increase immunological tolerance and changes the course of disease due to which demand for immunotherapy is increasing globally.

The global active pharmaceutical ingredient market is growing significantly, valuing at US$ 152.6 Bn in 2017 and expected to reach US$ 273.7 Bn by 2026. Worldwide growing chronic diseases along with rising incidences for respiratory, cardiovascular, and oncology drives the overall market growth during the forecast period. In addition, new technological progresses in biologics & other specialty drugs along with favorable public and private funding in the pharmaceutical sector across various developing countries will further assist in the API market growth.

Specimen validity test (SVT) primarily involve evaluation urine sample for detection of adulterant or dilution in drug testing specimen. Increase in number of drug abuse population and stringent regulatory guidelines enforced by regulatory agencies in developed countries such as United States are prime factors that are driving the growth of SVT reagent market. North America alone contributing more than 65 percent of total market share.

The pharmaceutical intermediates market is set to reach from US$ 25,965.0 Mn in 2018 to US$ 36,890.6 Mn by 2027 at a compound annual growth rate (CAGR) of 4.0% during the forecast period from 2019 to 2027. Significant rise in drug formulation and research activities and supportive regulatory environment provided by global healthcare agencies will consolidate the pharmaceutical intermediates market during the forecast period.

The global post-traumatic stress disorder therapeutics market expected to reach 10,679.5 Mn by 2026 with CAGR of 4.5% during the forecast period from 2018 to 2026. Antidepressants including SSRIs (Zoloft and Paxil) are among the first line of treatment for PTSD, dominated the global market in 2017 and projected to retain its dominance during the forecast period. North America dominated the PTSD therapeutics market with more than 50% of market share for the year 2017. 

The global glycogen market volume was at 2,176.6 Ton in 2017, and expected to grow at 5.8% CAGR during the forecast period from 2018 to 2026. Glycogen is a multi-branched glucose polysaccharide that acts as an energy reservoir in animals, humans, bacteria and fungi.

Global TNF inhibitor market accounted for US$ 43,394.4 Mn in 2017 and expected to attain US$ 181,139.7 Mn in 2026 growing at a CAGR of 16.5% during the forecast period from 2018 to 2026.

Global painful diabetic neuropathy (PDN) drugs market accounted to US$ 4,811.8 Mn in 2017 and expected to attain US$ 8,962.0 by 2026 growing at a CAGR of 6.6% during the forecast period from 2018 to 2026. Of the various marketed drugs analyzed, Lyrica accounted for maximum market share in 2017 while Qutenza will exhibit fastest CAGR during the forecast period from 2018 to 2026. Lyrica and Cymbalta are the only recommended first line of therapy for PDN thus depicting dominance throughout the study period from 2016 to 2026.

Exaggerating regulatory compliance, efficient maintenance of product life cycle and the growing need of prompt patient reporting has boost the need for pharmacovigilance. Pharmaceutical companies are increasingly entering into long term arrangements with CROs and BPOs for performing pharmacovigilance activities initiating from drug discovery phase to post market surveillance.

Allergy is the immune reaction to foreign body called allergen; it may arise due to food consumed or inhaled into lungs or in contact with skin through injectable agent or touch. Allergic diseases rank fifth among the leading chronic diseases across all age groups in U.S. Over the period of 50 years of global industrialization, there is a substantial rise in prevalence of allergic diseases.